<SEC-DOCUMENT>0001558370-23-007578.txt : 20230502
<SEC-HEADER>0001558370-23-007578.hdr.sgml : 20230502
<ACCEPTANCE-DATETIME>20230502081811
ACCESSION NUMBER:		0001558370-23-007578
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230502
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230502
DATE AS OF CHANGE:		20230502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroBo Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		23876704

	BUSINESS ADDRESS:	
		STREET 1:		200 BERKELEY ST.
		STREET 2:		FL 19
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(857) 702-9600

	MAIL ADDRESS:	
		STREET 1:		200 BERKELEY ST.
		STREET 2:		FL 19
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemphire Therapeutics Inc.
		DATE OF NAME CHANGE:	20150331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nrbo-20230502x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.5.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/1/2023 11:29:36 PM -->
      <!-- iXBRL Library version: 1.0.8476.13996 -->
      <!-- iXBRL Service Job ID: 5a2ef39b-9748-4842-b6b9-83e0a595f263 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:nrbo="http://www.neurobopharma.com/20230502" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:EntityCentralIndexKey" id="Tc_ST2f4dFoMkaHhDh8pLn8cQ_2_1">0001638287</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:AmendmentFlag" id="Tc_MBzMIuSqVki46qBWsGQucQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="nrbo-20230502.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-02</xbrli:startDate><xbrli:endDate>2023-05-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_74f46e40_4aa0_47bf_ad99_396ff9d0620b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:DocumentType" id="Narr_1U4aiqINPE2vYFa-qNKhgw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_bBVS8XoM6keX_MZVd7mK6A"><b style="font-weight:bold;">May 2, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:EntityRegistrantName" id="Narr_x2xVlJ3tf0SXaGLPoTGOFA"><b style="font-weight:bold;">NEUROBO PHARMACEUTICALS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of Registrant as Specified in Its Charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:justify;border-bottom:1.0pt solid #000000;margin:0pt 0pt 12pt 0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><a id="_d5ce07d0_ce29_4089_a8db_59e70ca6af23"></a><a id="Tc_8Xl_XBMNx0a0x7fBlvB9yg_2_0"></a><a id="Tc_s7XoqQktIEi9x0vVqjMu0w_2_1"></a><a id="Tc_Ha46ESv040OLBeYmpqIcAA_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96.69%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_yz3ReTyzDk-2efxWjyZgkg_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:EntityFileNumber" id="Tc_ViR07IlYiEmLSHvOe0e6jg_1_1"><b style="font-size:9pt;font-weight:bold;">001-37809</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:32.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:EntityTaxIdentificationNumber" id="Tc_jTdDzM3FRkGFqbOtZBWVGw_1_2"><b style="font-size:9pt;font-weight:bold;">47-2389984</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission </b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:top;width:32.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer </b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:EntityAddressAddressLine1" id="Narr_-i6OY5l7-0y-b540sZ83iw"><b style="font-size:9pt;font-weight:bold;">200 Berkeley Street</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:EntityAddressAddressLine2" id="Narr_Cdht4BKf9kSUuqG47KwYFA"><b style="font-size:9pt;font-weight:bold;">19th Floor</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:EntityAddressCityOrTown" id="Narr_lccMUuJpD0mIUI4x7gYoDQ"><b style="font-size:9pt;font-weight:bold;">Boston</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_vylE0Slhh0C773xlvsj6zg"><b style="font-size:9pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:EntityAddressPostalZipCode" id="Narr_8pIfUf3YqUeDpYzHMdsT_w"><b style="font-size:9pt;font-weight:bold;">02116</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(Address of principal executive offices, including Zip Code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Registrant&#8217;s Telephone Number, Including Area Code: (</b><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:CityAreaCode" id="Narr_hLCYZgXszkeo7TiB07mhuA"><b style="font-weight:bold;">857</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:LocalPhoneNumber" id="Narr__-3cspvc6k293vA85la0Fw"><b style="font-weight:bold;">702-9600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1d8a0a2e_ed8b_49f3_847b_945d6015e8fe"></a><a id="Tc_XV8PCglorEGcD0ZsDi5qkw_1_1"></a><a id="Tc_ISRq5wJuKky3QUqiKuPhzA_2_1"></a><a id="Tc_LK6lfMgJcUeQpDMau9WFpQ_3_1"></a><a id="Tc_BRZlBxgLEU2SGFoin3pymw_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_jOWX9huegkWiOoOLXqC8_w_1_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425) </p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_-gXJ0xN5kEWj4uOhX0Qmug_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_muKSkxK8wkSwTBTgD0hN7g_3_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_7V0SV-Rp4UeuLXucncd3Ng_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2f8c0dfc_b9c1_4816_bf8a_b07830a0b72b"></a><a id="Tc_9qZXWvvjjUO43PG0gpRSKQ_1_0"></a><a id="Tc_-aWSOnaCiEO21tsDtZrZEw_1_2"></a><a id="Tc_6ReGY8_a_Ue8a45fzjvhjA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading</b><br /><b style="font-weight:bold;">Symbol(s)</b></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:41.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:39.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:Security12bTitle" id="Tc_J6_O_xC8ikGJv3t-GUpHQg_2_0"><b style="font-weight:bold;">Common Stock, par value $0.001 per share</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" name="dei:TradingSymbol" id="Tc_qwoJTvzJMkeaGu-Jcy7-KA_2_2"><b style="font-weight:bold;">NRBO</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:41.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_yGNP5xYbzUiys-Bg4a0rNg_2_4"><b style="font-weight:bold;">The Nasdaq Stock Market LLC</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Emerging growth company&#160;<ix:nonNumeric contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_jTjIc1a1EECBVPdyvb_I_Q"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_8ce4aa76_b65c_41e7_bb11_c9a4ad9ec34f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 8.01</b>&#160;<b style="font-weight:bold;">Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 2 2023, NeuroBo Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration had cleared an Investigational New Drug application for a Phase 2a clinical trial of DA-1241 for the treatment of nonalcoholic steatohepatitis. &#160;A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Current Report on Form 8-K, and the inclusion of such website addresses in this Current Report on Form 8-K by incorporation by reference of the press release is as inactive textual references only.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:58.3pt;text-indent:-58.3pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:58.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">Item 9.01.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">(d) Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:86.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;">99.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 6pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nrbo-20230502xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated May 2, 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;">104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 6pt 0pt;">Cover Page Interactive Data File (embedded within Inline XBRL document).</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_c7630700_22f7_4a0c_8771_862f2af85453"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:44.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:51.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:55.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">N</b><b style="font-weight:bold;">EURO</b><b style="font-size:10pt;font-weight:bold;">B</b><b style="font-weight:bold;">O</b><b style="font-size:10pt;font-weight:bold;"> P</b><b style="font-weight:bold;">HARMACEUTICALS</b><b style="font-size:10pt;font-weight:bold;">, I</b><b style="font-weight:bold;">NC.</b></p></td></tr><tr><td style="vertical-align:top;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 2, 2023</p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:51.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joseph Hooker</p></td></tr><tr><td style="vertical-align:top;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joseph Hooker</p></td></tr><tr><td style="vertical-align:top;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Interim President and Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:top;width:44.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nrbo-20230502xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/1/2023 11:29:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;"><img src="nrbo-20230502xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:57.27pt;width:171.48pt;"></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial</b><b style="font-size:13pt;font-weight:bold;"><br></b><b style="font-size:13pt;font-weight:bold;">of DA-1241 for the Treatment of NASH</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:11pt;font-style:italic;">Initiation of Phase 2a Clinical Trial Expected to Occur in Q3 2023</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-size:11pt;font-weight:bold;">BOSTON, May 2, 2023 &#8211; NeuroBo Pharmaceuticals, Inc. </b><font style="font-size:11pt;">(Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist. The company plans to initiate a two-part, Phase 2a clinical trial of DA-1241, </font><font style="font-size:11pt;">for the treatment of nonalcoholic steatohepatitis </font><font style="font-size:11pt;">(NASH), in the third quarter of 2023.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">&#8220;Clearance of the IND for DA-1241 brings us one step closer to our goal of bringing this very promising cardiometabolic asset into clinical trials in patients with NASH, for which there is currently no approved treatment,&#8221; stated Joe Hooker, Interim President and Chief Executive Officer of NeuroBo. &#8220;In Phase 1a/1b clinical studies, DA-1241 was well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Importantly, preclinical studies demonstrated that DA-1241 attenuated NASH progression by reducing pro-inflammatory cytokines and chemokines, stellate cell activation, and collagen deposition in the liver, thereby improving inflammation, hepatic steatosis, and fibrosis. In those studies, DA-1241 also improved both lipid metabolism and glucose control. For these reasons, we believe that the mechanism of action of DA-1241 will translate into a safe and effective treatment for NASH. We are eager to initiate the two-part, Phase 2a clinical trial of DA-1241, which we expect will occur in the third quarter of this year. The two-part design provides optionality for an interim analysis in the first half of 2024 and we anticipate full data in the second half of 2024.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">&quot;Looking ahead, we expect additional, near-term value creating milestones, including advancement of DA-1726, our second asset, through the IND process, with the goal of initiating a Phase 1a safety study in the first half of 2024 and an expected data readout in the second half of 2024. DA-1726 is a novel oxyntomodulin (OXM) analogue that acts as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. The drug candidate is in development for the treatment of obesity and has demonstrated superior body weight loss in preclinical studies compared with other selective GLP1R agonists.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">&quot;It is truly an exciting time at NeuroBo, following the recent in-licensing of DA-1241 and DA-1726, with a new focus on cardiometabolic diseases and the enormous NASH, obesity, and T2DM markets.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">The two-part, Phase 2a trial of DA-1241 is designed to be a 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel clinical study to evaluate the efficacy and safety of DA-1241 in subjects with presumed NASH and confirmed pre-diabetes or T2DM. Part 1 will explore the efficacy of DA-1241 versus placebo, and is expected to enroll 49 subjects, with a planned maximum of 55 subjects to account for early discontinuations. Subjects will be randomized in a 1:2:1 ratio into 3 treatment groups: DA-1241 50 mg, DA-1241 100 mg, or placebo. Part 2 will explore the efficacy of DA-1241 in combination with sitagliptin, versus placebo, and will begin after completion of a confirmatory preclinical safety study of DA-1241 in combination with sitagliptin. It is expected to enroll 37 subjects, with a planned maximum of 43 subjects to account for early discontinuations, and subjects will be randomized in 2:1 ratio into 2 treatment groups: DA-1241 </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">100&#160;mg/sitagliptin 100 mg or placebo. Randomization of Part 1 and Part 2 will be stratified by T2DM status at baseline.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">For both Part 1 and Part 2, the primary endpoint is the change from baseline in alanine transaminase (ALT) levels at Week 16. Secondary efficacy endpoints include the proportion of subjects with normalization of ALT, relative percent change in liver fat fraction from baseline, absolute change in liver fat from baseline, and proportion of subjects with a 30% or more reduction in liver fat from baseline, among others. Safety will be evaluated by monitoring adverse events (AEs), serious adverse events (SAEs) and AEs leading to discontinuation and laboratory abnormalities.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">About DA-1241</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both NASH and T2DM. In preclinical studies, DA-1241 demonstrated that GPR-119 agonism promotes release of the key gut peptides GLP-1, GIP, and PYY, which have a beneficial effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of NASH and T2DM whereby DA-1241 reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. Furthermore, in Phase&#160;1a and 1b trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">About NeuroBo Pharmaceuticals</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Non-Alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, which promotes the release of key gut peptides GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin (OXM) analogue that acts as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">For more information, please visit&#160;</font><u style="color:#0000ff;font-size:11pt;text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">www.neurobopharma.com</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Forward Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the closing of the offering of securities. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercial strategy, the timeline for regulatory submissions, regulatory steps and potential regulatory approval of our current and future product candidates, the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of NeuroBo; the ability to integrate the new product candidates into NeuroBo&#8217;s business in a timely and cost-efficient manner; the cooperation of our contract manufacturers, clinical study partners and others involved in the development of our current and future product candidates; our ability to initiate and complete clinical </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">trials on a timely basis; our ability to recruit subjects for our clinical trials; costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; changes in applicable laws or regulations; effects of changes to NeuroBo&#8217;s stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. NeuroBo does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Contact:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Rx Communications Group</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Michael Miller</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">+1-917-633-6086</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><u style="color:#0000ff;font-size:11pt;text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">mmiller@rxir.com</u></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>nrbo-20230502xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nrbo-20230502xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !U 5P# 2(  A$! Q$!_\0
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M8,\\=M"\LTB11(-S.[!54>I)Z5!IVJV6L6_GV%W!>P9V^;;RK(N?3()%<O\
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M#ZU\:([_ &DPZ;:O,QQT8\+_ %K]'*^-XDFI8N,5T7^9]'EZ_=7\S/\ $/\
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MU]Y.ZEED:GQZ?=S>[^!\!"SCFDJ?P:_^!<OO?B?.WP-_8K\,?%+X8:-XFO\
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M\=:%X1O]&LM7U".RN=8N?LEE&X),TF/NC'3J.3QDCUJK\+O^2;^&/^P;;_\
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MQ)IZ>'_[;\YGTWR/M ECC9B4QG(4#<>.V,UYYXDD7_AFZ];<,?\ "/\ 7/\
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MJ]\+/^2;^&?^P=!_Z *XK]FB*&?P9JFIS8;7+[6+U]3E;_6&99F4*QZ_*H4
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MME!:6T:PVT$:Q11KT15& !] *GHHKE;OJSK22T04444AA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nrbo-20230502.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/1/2023 11:29:40 PM-->
<!--Modified on: 5/1/2023 11:29:40 PM-->
<xsd:schema targetNamespace="http://www.neurobopharma.com/20230502" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:nrbo="http://www.neurobopharma.com/20230502" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20230502_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20230502_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/cef/2022" schemaLocation="https://xbrl.sec.gov/cef/2022/cef-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>nrbo-20230502_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/1/2023 11:29:40 PM-->
<!--Modified on: 5/1/2023 11:29:40 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>nrbo-20230502_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/1/2023 11:29:40 PM-->
<!--Modified on: 5/1/2023 11:29:40 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="nrbo-20230502.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2022/cef-2022.xsd#N2" roleURI="http://xbrl.sec.gov/cef/role/N2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638185805805682733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638185805805682733" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638185805805682733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638185805805682733" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638185805805682733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638185805805682733" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638185805805682733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638185805805682733" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638185805805682733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638185805805682733" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638185805805682733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638185805805682733" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638185805805692754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638185805805692754" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638185805805692754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638185805805692754" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638185805805692754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638185805805692754" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638185805805692754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638185805805692754" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638185805805692754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638185805805692754" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638185805805692754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638185805805692754" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638185805805692754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638185805805692754" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638185805805692754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638185805805692754" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638185805805692754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638185805805692754" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638185805805692754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638185805805692754" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638185805805692754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638185805805692754" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638185805805702733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638185805805702733" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638185805805702733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638185805805702733" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638185805805702733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638185805805702733" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638185805805702733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638185805805702733" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638185805805702733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638185805805702733" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638185805805702733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638185805805702733" order="23" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cef/role/N2" xlink:type="extended" xlink:title="995470 - Disclosure - N-2" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140601408227152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-37809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROBO PHARMACEUTICALS,&#160;INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2389984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Berkeley Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">19th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">702-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRBO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140601408151408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>N-2<br></strong></div></th>
<th class="th"><div>May 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-37809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROBO PHARMACEUTICALS,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Berkeley Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">19th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">702-9600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>nrbo-20230502x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nrbo-20230502.xsd" xlink:type="simple"/>
    <context id="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2023-05-02</startDate>
            <endDate>2023-05-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_ST2f4dFoMkaHhDh8pLn8cQ_2_1">0001638287</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_MBzMIuSqVki46qBWsGQucQ_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Narr_1U4aiqINPE2vYFa-qNKhgw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Narr_bBVS8XoM6keX_MZVd7mK6A">2023-05-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Narr_x2xVlJ3tf0SXaGLPoTGOFA">NEUROBO PHARMACEUTICALS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_yz3ReTyzDk-2efxWjyZgkg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_ViR07IlYiEmLSHvOe0e6jg_1_1">001-37809</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_jTdDzM3FRkGFqbOtZBWVGw_1_2">47-2389984</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Narr_-i6OY5l7-0y-b540sZ83iw">200 Berkeley Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Narr_Cdht4BKf9kSUuqG47KwYFA">19th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Narr_lccMUuJpD0mIUI4x7gYoDQ">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Narr_vylE0Slhh0C773xlvsj6zg">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Narr_8pIfUf3YqUeDpYzHMdsT_w">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Narr_hLCYZgXszkeo7TiB07mhuA">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Narr__-3cspvc6k293vA85la0Fw">702-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_jOWX9huegkWiOoOLXqC8_w_1_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_-gXJ0xN5kEWj4uOhX0Qmug_2_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_muKSkxK8wkSwTBTgD0hN7g_3_0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_7V0SV-Rp4UeuLXucncd3Ng_4_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_J6_O_xC8ikGJv3t-GUpHQg_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_qwoJTvzJMkeaGu-Jcy7-KA_2_2">NRBO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Tc_yGNP5xYbzUiys-Bg4a0rNg_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg"
      id="Narr_jTjIc1a1EECBVPdyvb_I_Q">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M*-L O\^D-*\5FTQ5N7#_-U!+ P04    " !%0J)6GZ ;\+$"  #B#   #0
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MFKWZ\X'U/+_%K7V)Z]#?R>7C -[/2]]02P,$%     @ 14*B5FZG)+P> 0
M5P0  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULQ93/3L,P#,9?I<IU:C)VX(#6
M78 K[, +A-9=H^:?8F]T;X_;;I- HV(J$I=&C>WOY_B+LGX[1L"L<]9C(1JB
M^* 4E@TXC3)$\!RI0W*:^#?M5-1EJW>@5LOEO2J#)_"44Z\A-NLGJ/7>4O;<
M\3::X N1P*+('L?$GE4(':,UI2:.JX.OOE'R$T%RY9"#C8FXX 2AKA+ZR,^
M4]WK 5(R%61;G>A%.\Y2G55(1PLHIR6N]!CJVI10A7+ON$1B3* K; #(63F*
M+J;)Q!.&\7LWFS_(3 $Y<YM"1'8LP>VXLR5]=1Y9"!*9Z2->B"P]^WS0NUU!
M]4LVC_<CI';P ]6PS)_Q5X\O^C?VL?K'/MY#:/_ZJO>K=-KX,U\-[\GF$U!+
M 0(4 Q0    ( $5"HE8'04UB@0   +$    0              "  0    !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 14*B5KL:P"GO    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M14*B5IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !%0J)6&#CHXW\$  !+$0  &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M14*B5OUK.&I# P  %PL  !@              ("!PPP  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( $5"HE:?H!OPL0(  .(,   -
M          "  3P0  !X;"]S='EL97,N>&UL4$L! A0#%     @ 14*B5I>*
MNQS     $P(   L              ( !&!,  %]R96QS+RYR96QS4$L! A0#
M%     @ 14*B5@UAX(=0 0  Q0(   \              ( ! 10  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( $5"HE:-]RQ:M    (D"   :
M      "  7X5  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( $5"HE9NIR2\'@$  %<$   3              "  6H6  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     *  H A (  +D7      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nrbo-20230502x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nrbo-20230502x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995470 - Disclosure - N-2</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cef/role/N2</Role>
      <ShortName>N-2</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="nrbo-20230502x8k.htm">nrbo-20230502x8k.htm</File>
    <File>nrbo-20230502.xsd</File>
    <File>nrbo-20230502_lab.xml</File>
    <File>nrbo-20230502_pre.xml</File>
    <File>nrbo-20230502xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nrbo-20230502x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "nrbo-20230502x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nrbo-20230502_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nrbo-20230502_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nrbo-20230502.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/2006/xbrldi-2006.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/cef/2022/cef-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022_lab.xsd"
     ]
    }
   },
   "elementCount": 199,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nrbo",
   "nsuri": "http://www.neurobopharma.com/20230502",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20230502x8k.htm",
      "contextRef": "Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20230502x8k.htm",
      "contextRef": "Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg",
      "decimals": null,
      "lang": "en-US",
      "name": "dei:DocumentPeriodEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20230502x8k.htm",
      "contextRef": "Duration_5_2_2023_To_5_2_2023_MB47KF81mEWbHu_otbNzKg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityFileNumber",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "995470 - Disclosure - N-2",
     "menuCat": "Notes",
     "order": "2",
     "role": "http://xbrl.sec.gov/cef/role/N2",
     "shortName": "N-2",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 0,
   "tag": {
    "cef_AcquiredFundFeesAndExpensesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundFeesAndExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundFeesAndExpensesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses [Percent]"
       }
      }
     },
     "localname": "AcquiredFundFeesAndExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AcquiredFundFeesEstimatedNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees Estimated, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundFeesEstimatedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundIncentiveAllocationNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Incentive Allocation, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundIncentiveAllocationNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Total Annual Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AllRisksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Risks:"
       }
      }
     },
     "localname": "AllRisksMember",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "cef_AllSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Securities:"
       }
      }
     },
     "localname": "AllSecuritiesMember",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "cef_AnnualCoverageReturnRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Coverage Return Rate [Percent]"
       }
      }
     },
     "localname": "AnnualCoverageReturnRatePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualDividendPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment"
       }
      }
     },
     "localname": "AnnualDividendPayment",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualDividendPaymentCurrent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Current"
       }
      }
     },
     "localname": "AnnualDividendPaymentCurrent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualDividendPaymentInitial": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Initial"
       }
      }
     },
     "localname": "AnnualDividendPaymentInitial",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Expenses [Table Text Block]"
       }
      }
     },
     "localname": "AnnualExpensesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AnnualInterestRateCurrentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Current [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRateCurrentPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualInterestRateInitialPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Initial [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRateInitialPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualInterestRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRatePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_BasisOfTransactionFeesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Transaction Fees, Note [Text Block]"
       }
      }
     },
     "localname": "BasisOfTransactionFeesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_BdcFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BDC File Number"
       }
      }
     },
     "localname": "BdcFileNumber",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "cef_BusinessDevelopmentCompanyFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Development Company [Flag]"
       }
      }
     },
     "localname": "BusinessDevelopmentCompanyFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]"
       }
      }
     },
     "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_CapitalStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock [Table Text Block]"
       }
      }
     },
     "localname": "CapitalStockTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_DistributionServicingFeesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution/Servicing Fees [Percent]"
       }
      }
     },
     "localname": "DistributionServicingFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DistributionsMayReducePrincipalTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributions May Reduce Principal [Text Block]"
       }
      }
     },
     "localname": "DistributionsMayReducePrincipalTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_DividendAndInterestExpensesOnShortSalesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend and Interest Expenses on Short Sales [Percent]"
       }
      }
     },
     "localname": "DividendAndInterestExpensesOnShortSalesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DividendExpenseOnPreferredSharesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Expenses on Preferred Shares [Percent]"
       }
      }
     },
     "localname": "DividendExpenseOnPreferredSharesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DividendReinvestmentAndCashPurchaseFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Reinvestment and Cash Purchase Fees"
       }
      }
     },
     "localname": "DividendReinvestmentAndCashPurchaseFees",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_EffectsOfLeveragePurposeTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage, Purpose [Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeveragePurposeTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_EffectsOfLeverageTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Table Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeverageTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_EffectsOfLeverageTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeverageTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ExpenseExampleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example [Table Text Block]"
       }
      }
     },
     "localname": "ExpenseExampleTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ExpenseExampleYear01": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Year 01"
       }
      }
     },
     "localname": "ExpenseExampleYear01",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to10": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 10"
       }
      }
     },
     "localname": "ExpenseExampleYears1to10",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 3"
       }
      }
     },
     "localname": "ExpenseExampleYears1to3",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to5": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 5"
       }
      }
     },
     "localname": "ExpenseExampleYears1to5",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_FeeTableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Table [Abstract]"
       }
      }
     },
     "localname": "FeeTableAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_FinancialHighlightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Highlights [Abstract]"
       }
      }
     },
     "localname": "FinancialHighlightsAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_GeneralDescriptionOfRegistrantAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Description of Registrant [Abstract]"
       }
      }
     },
     "localname": "GeneralDescriptionOfRegistrantAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_HighestPriceOrBid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid"
       }
      }
     },
     "localname": "HighestPriceOrBid",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_HighestPriceOrBidNav": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, NAV"
       }
      }
     },
     "localname": "HighestPriceOrBidNav",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_HighestPriceOrBidPremiumDiscountToNavPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "HighestPriceOrBidPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationMaximumPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Maximum [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationMaximumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationMinimumPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Minimum [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationMinimumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveFeesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Fees [Percent]"
       }
      }
     },
     "localname": "IncentiveFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_InterestExpensesOnBorrowingsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expenses on Borrowings [Percent]"
       }
      }
     },
     "localname": "InterestExpensesOnBorrowingsPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IntervalFundFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interval Fund [Flag]"
       }
      }
     },
     "localname": "IntervalFundFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_InvestmentObjectivesAndPracticesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Objectives and Practices [Text Block]"
       }
      }
     },
     "localname": "InvestmentObjectivesAndPracticesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LatestNav": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest NAV"
       }
      }
     },
     "localname": "LatestNav",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LatestPremiumDiscountToNavPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "LatestPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_LatestSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Share Price"
       }
      }
     },
     "localname": "LatestSharePrice",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LoanServicingFeesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Servicing Fees [Percent]"
       }
      }
     },
     "localname": "LoanServicingFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_LongTermDebtDividendsAndCovenantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Dividends and Covenants [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtDividendsAndCovenantsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Issuance and Substitution [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Principal"
       }
      }
     },
     "localname": "LongTermDebtPrincipal",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtStructuringTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Structuring [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtStructuringTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt [Table Text Block]"
       }
      }
     },
     "localname": "LongTermDebtTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtTitleTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Title [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LowestPriceOrBid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid"
       }
      }
     },
     "localname": "LowestPriceOrBid",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LowestPriceOrBidNav": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, NAV"
       }
      }
     },
     "localname": "LowestPriceOrBidNav",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LowestPriceOrBidPremiumDiscountToNavPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "LowestPriceOrBidPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fee not based on Net Assets, Note [Text Block]"
       }
      }
     },
     "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ManagementFeesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fees [Percent]"
       }
      }
     },
     "localname": "ManagementFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_NetExpenseOverAssetsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Expense over Assets [Percent]"
       }
      }
     },
     "localname": "NetExpenseOverAssetsPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_NewCefOrBdcRegistrantFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "New CEF or BDC Registrant [Flag]"
       }
      }
     },
     "localname": "NewCefOrBdcRegistrantFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_NoPublicTradingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Public Trading [Text Block]"
       }
      }
     },
     "localname": "NoPublicTradingTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_NoTradingHistoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading History [Text Block]"
       }
      }
     },
     "localname": "NoTradingHistoryTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherAnnualExpense1Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 1.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 1 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense1Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpense2Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 2.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 2 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense2Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpense3Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 3.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 3 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense3Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherAnnualExpensesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_OtherAnnualExpensesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherExpensesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "OtherExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherFeederFundExpensesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Feeder Fund Expenses [Percent]"
       }
      }
     },
     "localname": "OtherFeederFundExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherMasterFundExpensesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Master Fund Expenses [Percent]"
       }
      }
     },
     "localname": "OtherMasterFundExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Securities [Table Text Block]"
       }
      }
     },
     "localname": "OtherSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherSecurityDescriptionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Description [Text Block]"
       }
      }
     },
     "localname": "OtherSecurityDescriptionTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherSecurityTitleTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Title [Text Block]"
       }
      }
     },
     "localname": "OtherSecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherTransactionExpense1Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 1.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 1 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense1Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpense2Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 2.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 2 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense2Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpense3Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 3.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 3 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense3Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherTransactionExpensesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_OtherTransactionExpensesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionFeesBasisMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisMaximum",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_OtherTransactionFeesBasisMaximumPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum [Percent]"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisMaximumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionFeesBasisNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Note [Text Block]"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherTransactionFeesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees, Note [Text Block]"
       }
      }
     },
     "localname": "OtherTransactionFeesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OutstandingSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Securities [Table Text Block]"
       }
      }
     },
     "localname": "OutstandingSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OutstandingSecurityAuthorizedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Authorized [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityAuthorizedShares",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityHeldShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Held [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityHeldShares",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityNotHeldShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Not Held [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityNotHeldShares",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityTitleTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Title [Text Block]"
       }
      }
     },
     "localname": "OutstandingSecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PreferredStockRestrictionsArrearageTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Arrearage [Text Block]"
       }
      }
     },
     "localname": "PreferredStockRestrictionsArrearageTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PreferredStockRestrictionsOtherTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Other [Text Block]"
       }
      }
     },
     "localname": "PreferredStockRestrictionsOtherTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PrimaryShelfFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf [Flag]"
       }
      }
     },
     "localname": "PrimaryShelfFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_PrimaryShelfQualifiedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf Qualified [Flag]"
       }
      }
     },
     "localname": "PrimaryShelfQualifiedFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_ProspectusLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus [Line Items]"
       }
      }
     },
     "localname": "ProspectusLineItems",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "xbrltype": "stringItemType"
    },
    "cef_ProspectusTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus:"
       }
      }
     },
     "localname": "ProspectusTable",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_PurposeOfFeeTableNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purpose of Fee Table , Note [Text Block]"
       }
      }
     },
     "localname": "PurposeOfFeeTableNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RegisteredClosedEndFundFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Closed-End Fund [Flag]"
       }
      }
     },
     "localname": "RegisteredClosedEndFundFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_ReturnAtMinusFivePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Five [Percent]"
       }
      }
     },
     "localname": "ReturnAtMinusFivePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtMinusTenPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Ten [Percent]"
       }
      }
     },
     "localname": "ReturnAtMinusTenPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtPlusFivePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Five [Percent]"
       }
      }
     },
     "localname": "ReturnAtPlusFivePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtPlusTenPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Ten [Percent]"
       }
      }
     },
     "localname": "ReturnAtPlusTenPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtZeroPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Zero [Percent]"
       }
      }
     },
     "localname": "ReturnAtZeroPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_RightsLimitedByOtherSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "localname": "RightsLimitedByOtherSecuritiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Subject to Other than Majority Vote [Text Block]"
       }
      }
     },
     "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RiskAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Axis]"
       }
      }
     },
     "localname": "RiskAxis",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_RiskFactorsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Factors [Table Text Block]"
       }
      }
     },
     "localname": "RiskFactorsTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RiskTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Text Block]"
       }
      }
     },
     "localname": "RiskTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SalesLoadPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Load [Percent]"
       }
      }
     },
     "localname": "SalesLoadPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_SecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security [Axis]"
       }
      }
     },
     "localname": "SecurityAxis",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_SecurityDividendsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Dividends [Text Block]"
       }
      }
     },
     "localname": "SecurityDividendsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liabilities [Text Block]"
       }
      }
     },
     "localname": "SecurityLiabilitiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityLiquidationRightsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liquidation Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityLiquidationRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityObligationsOfOwnershipTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Obligations of Ownership [Text Block]"
       }
      }
     },
     "localname": "SecurityObligationsOfOwnershipTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityPreemptiveAndOtherRightsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Preemptive and Other Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityPreemptiveAndOtherRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityTitleTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Title [Text Block]"
       }
      }
     },
     "localname": "SecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityVotingRightsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Voting Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityVotingRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount"
       }
      }
     },
     "localname": "SeniorSecuritiesAmount",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_SeniorSecuritiesAverageMarketValuePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Average Market Value per Unit"
       }
      }
     },
     "localname": "SeniorSecuritiesAverageMarketValuePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Averaging Method, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesCoveragePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit"
       }
      }
     },
     "localname": "SeniorSecuritiesCoveragePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesHeadingsNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Headings, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHeadingsNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Annualized, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Audited, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Involuntary Liquidating Preference per Unit"
       }
      }
     },
     "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities [Table Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SharePriceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price [Table Text Block]"
       }
      }
     },
     "localname": "SharePriceTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SharePricesNotActualTransactionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Prices Not Actual Transactions [Text Block]"
       }
      }
     },
     "localname": "SharePricesNotActualTransactionsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ShareholderTransactionExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Transaction Expenses [Table Text Block]"
       }
      }
     },
     "localname": "ShareholderTransactionExpensesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_TotalAnnualExpensesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Annual Expenses [Percent]"
       }
      }
     },
     "localname": "TotalAnnualExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_UnderwritersCompensationPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters Compensation [Percent]"
       }
      }
     },
     "localname": "UnderwritersCompensationPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_WaiversAndReimbursementsOfFeesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Waivers and Reimbursements of Fees [Percent]"
       }
      }
     },
     "localname": "WaiversAndReimbursementsOfFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_WarrantsOrRightsCalledAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Amount"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledAmount",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_WarrantsOrRightsCalledPeriodDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Period [Date]"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledPeriodDate",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "cef_WarrantsOrRightsCalledTitleTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Title"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_WarrantsOrRightsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Exercise Price"
       }
      }
     },
     "localname": "WarrantsOrRightsExercisePrice",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_AdditionalSecurities462b": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "localname": "AdditionalSecurities462b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "localname": "AdditionalSecurities462bFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "localname": "AdditionalSecuritiesEffective413b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings.",
        "label": "Approximate Date of Commencement of Proposed Sale to Public"
       }
      }
     },
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateOrAsapItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r7",
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DelayedOrContinuousOffering": {
     "auth_ref": [
      "r9",
      "r10",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "localname": "DelayedOrContinuousOffering",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "auth_ref": [
      "r9",
      "r10",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EffectiveAfter60Days486a": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "localname": "EffectiveAfter60Days486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnDate486a": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnDate486b": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnSetDate486a": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnSetDate486b": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling462e": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "localname": "EffectiveUponFiling462e",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling486b": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "localname": "EffectiveUponFiling486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "localname": "EffectiveWhenDeclaredSection8c",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInvCompanyType": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product).",
        "label": "Entity Inv Company Type"
       }
      }
     },
     "localname": "EntityInvCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "invCompanyType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExhibitsOnly462d": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "localname": "ExhibitsOnly462d",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "localname": "ExhibitsOnly462dFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_InvestmentCompanyActFileNumber": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "localname": "InvestmentCompanyActFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_InvestmentCompanyActRegistration": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "localname": "InvestmentCompanyActRegistration",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "localname": "NewEffectiveDateForPreviousFiling",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462c": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "localname": "NoSubstantiveChanges462c",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "localname": "NoSubstantiveChanges462cFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_PostEffectiveAmendment": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "localname": "PostEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PostEffectiveAmendmentNumber": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective.",
        "label": "Post-Effective Amendment Number"
       }
      }
     },
     "localname": "PostEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreEffectiveAmendment": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "localname": "PreEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreEffectiveAmendmentNumber": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.",
        "label": "Pre-Effective Amendment Number"
       }
      }
     },
     "localname": "PreEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form N-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form N-4",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form N-6",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form S-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Investment Company Act",
   "Number": "270",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "313",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "413",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r20": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r21": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r22": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r23": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "e",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r24": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r25": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r26": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r27": {
   "Name": "Securities Act",
   "Publisher": "SEC",
   "Section": "8",
   "Subsection": "c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Form F-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-23-007578-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-007578-xbrl.zip
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M,0R?(K=EC/^X^?A1^T3/Y.ZT*>Y(]9*SB_I-I\*;TZ9+@<4-V=1M]:JI:&@
M*=UT/6@J4U#TL4=A;"6>C+&GFQ@21.B5\AQHNET+(\G#-,:=LFF*$2F>G>MG
M.0)6=<)17&;6R5-(9/FYCN+F#NH^B?1,"M^=1Z+^#'VF2#D]T1!43T\&R(.
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M_Y=8_G]LG_T+4$L! A0#%     @ 14*B5MZU"PJ% P  U@P  !$
M     ( !     &YR8F\M,C R,S U,#(N>'-D4$L! A0#%     @ 14*B5D4X
M@E [ 0  > (  !4              ( !M ,  &YR8F\M,C R,S U,#)?;&%B
M+GAM;%!+ 0(4 Q0    ( $5"HE8JGN9LLP0  + H   5              "
M 2(%  !N<F)O+3(P,C,P-3 R7W!R92YX;6Q02P$"% ,4    " !%0J)6/0 O
MF785  #THP  %               @ $("@  ;G)B;RTR,#(S,#4P,G@X:RYH
M=&U02P$"% ,4    " !%0J)6Q5T(F?,/   V/   &               @ &P
M'P  ;G)B;RTR,#(S,#4P,GAE>#DY9#$N:'1M4$L%!@     %  4 30$  -DO
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
